The role of polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene in retinal vein occlusion (RVO) is a theme of discussion since the first reports of RVO in patients with MTHFR C677T mutation and without classic acquired risk factors for retinal vascular disease. The association between MTHFR polymorphisms and RVO has been studied over the last 20 years producing conflicting results. This review aims to summarize the literature concerning the role MTHFR polymorphisms as risk factors for RVO.
RehakMKrcovaVSlavikL, et al. The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. Can J Ophthalmol2010; 45(2): 171–175.
2.
ArsèneSDelahousseBReginaS, et al. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost. 2005; 94(1): 101–106.
3.
SelhubJJacquesPFRushD, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc1993; 270(22): 2693–2698.
4.
JacquesPFBostomAGWilliamsRR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation1996; 93(1): 7–9.
5.
D’AngeloACoppolaAMadonnaP, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events. Thromb Haemost. 2000; 83(4): 563–570.
6.
YadavUKumarPGuptaS, et al. Distribution of MTHFR C677T Gene Polymorphism in Healthy North Indian Population and an Updated Meta-analysis. Indian J Clin Biochem. 2017; 32(4): 399–410.
7.
Afaque AlamM. Methylenetetrahydrofolate reductase gene polymorphisms and cardiovascular diseases. Cell Dev Biol2016; 5(2): 1–4.
8.
KlaiSFekih-MrissaNEl HousainiS, et al. Association of MTHFR A1298C polymorphism (but not of MTHFR C677T) with elevated homocysteine levels and placental vasculopathies. Blood Coagul Fibrinolysis2011; 22(5): 374–378.
9.
CastroRRiveraIRavascoP, et al. 5,10-methylenetetrahydrofolate reductase 677C → T and 1298A → C mutations are genetic determinants of elevated homocysteine. QJM2003; 96(4): 297–303.
10.
ScheufeleTAPieroniCGBaumalCR.Methylene-tetrahydrofolate reductase gene mutation in a 16-year-old girl with combined central retinal vein occlusion/cilioretinal artery occlusion. Retin Cases Brief Rep2007; 1(3): 134–137.
11.
TurakaKZiemianskiMCBryanJS.Papillophlebitis in a young girl secondary to homozygous mutation of MTHFR C677T and A1298C genotypes. Retin Today. 2013.
12.
MradMWathekCSalehMB, et al. Association of methylenetetrahydrofolate reductase (A1298C and C677T) polymorphisms with retinal vein occlusion in Tunisian patients. Transfus Apher Sci2014; 50(2): 283–287.
13.
YiotiGGPanagiotouOAVartholomatosGA, et al. Genetic polymorphisms associated with retinal vein occlusion: A Greek case-control study and meta-analysis. Ophthalmic Genet2013; 34(3): 130–139.
14.
GiannakiKPolitouMRouvasA, et al. Retinal vein occlusion: Genetic predisposition and systemic risk factors. Blood Coagul Fibrinolysis. 2013; 24(3): 279–283.
15.
GhaznaviHSoheiliZSamieiS, et al. Plasma homocysteine levels, methylene tetrahydrofolate reductase A1298C gene polymorphism and risk of retinal vein thrombosis. Blood Coagul Fibrinolysis. 2016; 27(6): 679–683.
16.
KangSSZhouJWongPWK, et al. Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988; 43(4): 414–421.
17.
FrosstPBlomHJMilosR, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet1995; 10(1): 111–113.
18.
EngbersenAMTFrankenDGBoersGHJ, et al. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995; 56(1): 142–150.
19.
LoewensteinAWinderAGoldsteinM, et al. Bilateral retinal vein occlusion associated with 5,10- methylenetetrahydrofolate reductase mutation. Am J Ophthalmol. 1997; 127(6): 840–841.
20.
LoewensteinAGoldsteinMWinderA, et al. Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. Ophthalmology1999; 106(9): 1817–1820.
21.
SalomonOMoisseievJRosenbergN, et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis1998; 9(7): 617–622.
22.
MarcucciRBertiniLGiustiB, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost2001; 86(3): 772–776.
23.
MarcucciRGiustiBBettiI, et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res2003; 110(1): 7–12.
24.
RisseFFrankRDWeinbergerAWA. Thrombophilia in patients with retinal vein occlusion: A retrospective analysis. Ophthalmologica2014; 232(1): 46–52.
25.
RussoPDDamanteGPascaS, et al. Thrombophilic mutations as risk factor for retinal vein occlusion: A case-control study. Clin Appl Thromb2015; 21(4): 373–377.
26.
GlueckCJBellHVadlamaniL, et al. Heritable thrombophilia and hypofibrinolysis: Possible causes of retinal vein occlusion. Arch Ophthalmol1999; 117(1): 43–49.
27.
BoydSOwensDGinT, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and vWF in central retinal vein occlusion. Br J Ophthalmol2001; 85(11): 1313–1315.
28.
CahillMKarabatzakiMDonoghueC, et al. Thermolabile MTHFR genotype and retinal vascular occlusive disease. Br J Ophthalmol2001; 85(1): 88–90.
29.
DodsonPMHaynesJStarczynskiJ, et al. The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: A novel risk factor for retinal vein occlusion. Eye2003; 17(6): 772–777.
30.
ParodiMBDi CrecchioL.Hyperhomocysteinemia in central retinal vein occlusion in young adults. Semin Ophthalmol. 2003; 18(3): 154–159.
31.
GaoWWangYSZhangP, et al. MTHFR C677T mutation in central retinal vein occlusion: A case-control study in Chinese population. Thromb Res2008; 121(5): 699–703.
32.
KoyluMTKucukevciliogluMErdurmanFC, et al. Association of retinal vein occlusion, homocysteine, and the thrombophilic mutations in a Turkish population: A case-control study. Ophthalmic Genet2017; 38(4): 352–356.
33.
NemaNVermaSKumarR.Investigation of methylenetetrahydrofolate reductase C677T and factor v Leiden mutation as a genetic marker for retinal vein occlusion. Taiwan J Ophthalmol2018; 8(2): 99–103.
34.
VieiraMJCamposAdo CarmoA, et al. Thrombophilic risk factors for retinal vein occlusion. Sci Rep2019; 9(1): 18972.
35.
LarssonJHultbergBHillarpA.Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand2000; 78(3): 340–343.
36.
CrucianiFMoramarcoACurtoT, et al. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. Clin Ter2003; 154(5): 299–303.
37.
BiancardiALGadelhaTBorgesWIS, et al. Thrombophilic mutations and risk of retinal vein occlusion. Arq Bras Oftalmol2007; 70(6): 971–974.
38.
GallagherPMMeleadyRShieldsDC, et al. Homocysteine and risk of premature coronary heart disease: Evidence for a common gene mutation. Circulation1996; 94(9): 2154–2158.
39.
WegerMStangerODeutschmannH, et al. Hyperhomocyst(e)inemia, but not methylenetetrahydrofolate reductase C677T mutation, as a risk factor in branch retinal vein occlusion. Ophthalmology. 2002; 109(6): 1105–1109.
40.
WegerMStangerODeutschmannH, et al. Hyperho-mocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefe’s Arch Clin Exp Ophthalmol2002; 240(4): 286–290.
41.
McGimpseySJWoodsideJ V.BamfordL, et al. Retinal vein occlusion, homocysteine, and methylene tetrahydrofolate reductase genotype. Investig Ophthalmol Vis Sci2005; 46(12): 4712–4716.
42.
FerraziPDi MiccoPQuagliaI, et al. Homocysteine, MTHFR C677T gene polymorphism, folic acid and vitamin B 12 in patients with retinal vein occlusion. Thromb J2005; 3: 13.
43.
SottilottaGSiboniSMLatellaC, et al. Hyperhomo-cysteinemia and C677T MTHFR genotype in patients with retinal vein thrombosis. Clin Appl Thromb2010; 16(5): 549–553.
44.
DongNWangBChuL, et al. Plasma homocysteine concentrations in the acute phase after central retinal vein occlusion in a Chinese population. Curr Eye Res2013; 38(11): 1153–1158.
45.
DongNXuBTangX.Plasma homocysteine concentrations in acute and convalescent changes of central retinal vein occlusion in a chinese population. Investig Ophthalmol Vis Sci2014; 55(7): 4057.
46.
MinnitiGCalevoMGGiannattasioA, et al. Plasma homocysteine in patients with retinal vein occlusion. Eur J Ophthalmol. 2014; 24(5): 735–743.
47.
RefsumHUelandPMNygårdO, et al. Homocysteine and cardiovascular disease. Annu Rev Med. 1998; 12(2): 536–538.
48.
HarmonDLWoodsideJVYarnellJWG, et al. The common “thermolabile” variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. QJM1996; 89(8): 517–577.
49.
De FranchisRManciniFPD’AngeloA, et al. Elevated total plasma homocysteine and 677C→T mutation of the 5,10- methylenetetrahydrofolate reductase gene in thrombotic vascular disease. Am J Hum Genet1996; 59(1): 262–264.
50.
WilckenBBamforthFLiZ, et al. Geographical and ethnic variation of the 677C>T allele of 5, 10 methylenetetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas world wide. J Med Genet2003; 40(8): 619–625.
51.
Di CrecchioLParodiMBSanguinettiG, et al. Hyperhomocysteinemia and the methylenetetrahydrofolate reductase 677C-T mutation in patients under 50 years of age affected by central retinal vein occlusion. Ophthalmology2004; 111(5): 940–945.
52.
Fernández-VegaBÁlvarezLGarcíaM, et al. Association study of high-frequency variants of MTHFR gene with retinal vein occlusion in a Spanish population. Ophthalmic Genet2019; 40(4): 342–349.
53.
Di CapuaMCoppolaAAlbisinniR, et al. Cardiovascular risk factors and outcome in patients with retinal vein occlusion. J Thromb Thrombolysis2010; 30(1): 16–22.
54.
McGimpseySJWoodsideJVCardwellC, et al. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology2009; 116(9): 1778–1787.
55.
LiDZhouMPengX, et al. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: An updated meta-analysis. BMC Ophthalmol2014; 14: 147.
56.
CahillMTStinnettSSFekratS.Meta-analysis of plasma homocysteine, serum folate, serum vitamin B 12, and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol2003; 136(6): 1136–1350.
57.
LoewensteinAGoldsteinMWinderA, et al. Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. Ophthalmology1999; 106(9): 1817–1820.
58.
JanssenMCHden HeijerMCruysbergJRM, et al. Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost2005; 93(6): 1021–1026.
59.
WoodsideJVYarnellJWGMcMasterD, et al. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: A double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr1998; 67(5): 858–866.
60.
Ashfield-WattPALPullinCHWhitingJM, et al. Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: A randomized controlled trial. Am J Clin Nutr2002; 76(1): 180–186.
